Jacobs Levy Equity Management’s Metagenomi Therapeutics MGX Stock Holding History

Jacobs Levy Equity Management’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$512K	Buy	+382,153	New	+$594K	﹤0.01%	825
2025 Q4	–	Sell	-34,169	Closed	-$81K	–	1075
2025 Q3	$81K	Hold	34,169	–	–	﹤0.01%	944
2025 Q2	$50.6K	Sell	34,169 -32,013	-48%	-$50.1K	﹤0.01%	1016
2025 Q1	$90K	Hold	66,182	–	–	﹤0.01%	1049
2024 Q4	$239K	Sell	66,182 -70,442	-52%	-$170K	﹤0.01%	888
2024 Q3	$296K	Buy	136,624 +92,468	+209%	+$321K	﹤0.01%	886
2024 Q2	$180K	Buy	+44,156	New	+$303K	﹤0.01%	924

Other funds holding MGX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jacobs Levy Equity Management's MGX Position: Q1 2026 in Review

Jacobs Levy Equity Management opened a new position in Metagenomi Therapeutics (MGX) in Q1 2026: 382,153 shares worth $512K. The stake represents ﹤0.01% of the portfolio and ranks #825 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in MGX as recently as Q3 2025.

Jacobs Levy Equity Management first reported a position in MGX in Q2 2024 and has held it in 7 quarters since. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

Jacobs Levy Equity Management held 382,153 shares of Metagenomi Therapeutics worth $512K as of Q1 2026.
Metagenomi Therapeutics was a new Jacobs Levy Equity Management position in Q1 2026.
Metagenomi Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #825 holding.
Jacobs Levy Equity Management first reported a position in Metagenomi Therapeutics in Q2 2024 and has held it in 7 quarters since.
48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.